Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 5/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | ALPI | P09923 | 1/20 | 0.40 |
| ▸ | XIAP | P98170 | 1/20 | 0.40 |
| ▸ | GRB2 | P62993 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.36 |
| ▸ | USP2 | O75604 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
| ▸ | RECQL | P46063 | 2/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19337431 | 0.68 | SLC7A5 (0.40) | SLC7A5PTGS1PKMALPIXIAP | |
| SCHEMBL22605458 | 0.68 | SLC7A5 (0.40) | SLC7A5PTGS1PKMALPIXIAP | |
| SCHEMBL30861176 | 0.67 | HSD17B10 (0.39) | SLC7A5PTGS1PKMALPIXIAP | |
| SCHEMBL5300667 | 0.66 | SLC7A5 (0.44) | SLC7A5PTGS1PKMALPIXIAP | |
| SCHEMBL14441259 | 0.66 | SLC7A5 (0.44) | SLC7A5PTGS1PKMALPIXIAP | |
| SCHEMBL1640222 | 0.66 | SLC7A5 (0.44) | SLC7A5PTGS1PKMALPIXIAP | |
| SCHEMBL22914446 | 0.65 | SLC7A5 (0.40) | SLC7A5PTGS1PKMALPIXIAP | |
| SCHEMBL30466506 | 0.65 | USP2 (0.34) | SLC7A5PTGS1PKMALPIXIAP | |
| Phenylalanine SCHEMBL5402089 | 0.63 | SLC7A5 (0.81) | SLC7A5PTGS1PKMALPIXIAP | |
| SCHEMBL14023473 | 0.63 | SLC7A5 (0.41) | SLC7A5PTGS1PKMALPIXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0483261-A1 | HIRUDIN PEPTIDE DERIVATIVES | BIOGEN, INC. (US) | 1992-05-06 | — | — | EP | claimed |
| WO-1991001328-A1 | HIRUDIN PEPTIDE DERIVATIVES | BIOGEN, INC. (US) | 1991-02-07 | — | — | WO | claimed |
| US-7071299-B2 | Peptide and polypeptide inhibitors of complement C1s | ZYMOGENETICS, INC. (US) | 2006-07-04 | — | — | US | disclosed |
| US-20050267035-A1 | Peptide and polypeptide inhibitors of complement C1s | ZYMOGENETICS, INC. | 2005-12-01 | — | — | US | disclosed |
| EP-1349874-A2 | PEPTIDE AND POLYPEPTIDE INHIBITORS OF COMPLEMENT C1S | ZymoGenetics, Inc. (US) | 2003-10-08 | — | — | EP | disclosed |
| US-20020102256-A1 | Peptide and polypeptide inhibitors of complement C1s | ZYMOGENETICS, INC. | 2002-08-01 | — | — | US | disclosed |
| WO-2001098365-A2 | PEPTIDE AND POLYPEPTIDE INHIBITORS OF COMPLEMENT C1S | ZYMOGENETICS, INC. (US) | 2001-12-27 | — | — | WO | disclosed |
| US-5691311-A | Methods for coating invasive devices with inhibitors of thrombin | BIOGEN, INC. (US) | 1997-11-25 | — | — | US | disclosed |
| EP-0489070-B1 | NOVEL INHIBITORS OF THROMBIN | BIOGEN INC (US) | 1996-04-24 | — | — | EP | disclosed |
| US-5433940-A | Synthetic molecules mimic action of hirudin by binding to both the low affinity anion-binding exosite and the catalytic site of thrombin | BIOGEN, INC. (US) | 1995-07-18 | — | — | US | disclosed |
| US-5196404-A | Hirudin mimic, polypeptide, hirulog; bivalirudin FDA Orange book listed patent | BIOGEN, INC. (US) | 1993-03-23 | — | — | US | disclosed |
| EP-0489070-A1 | NOVEL INHIBITORS OF THROMBIN. | BIOGEN INC (US) | 1992-06-10 | — | — | EP | disclosed |
| EP-0483261-A1 | HIRUDIN PEPTIDE DERIVATIVES | BIOGEN, INC. (US) | 1992-05-06 | — | — | EP | disclosed |
| EP-0482069-A1 | COMBINATIONS AND METHODS FOR TREATING OR PREVENTING THROMBOTIC DISEASES | BIOGEN, INC. (US) | 1992-04-29 | — | — | EP | disclosed |
| WO-1991002750-A1 | NOVEL INHIBITORS OF THROMBIN | BIOGEN, INC. (US) | 1991-03-07 | — | — | WO | disclosed |
| WO-1991001328-A1 | HIRUDIN PEPTIDE DERIVATIVES | BIOGEN, INC. (US) | 1991-02-07 | — | — | WO | disclosed |
| WO-1991001142-A1 | COMBINATIONS AND METHODS FOR TREATING OR PREVENTING THROMBOTIC DISEASES | BIOGEN, INC. (US) | 1991-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267035-A1 | Peptide and polypeptide inhibitors of complement C1s | C1S, C1QBP, C1R | SLC7A5 3648/4885PTGS1 2655/4885PKM 4050/4885 |
| US-20020102256-A1 | Peptide and polypeptide inhibitors of complement C1s | C1S, C1QBP, C1R | SLC7A5 3648/4885PTGS1 2655/4885PKM 4050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.